Resumo

SPERANZA SANCHEZ, Mario  e  SAENZ MADRIGAI, Manuel Eduardo. Heparinas de bajo peso molecular en el tratamiento de los síndromes coronarios agudos (SCA). Rev. costarric. cardiol [online]. 1999, vol.1, n.1, pp.38-42. ISSN 1409-4142.

The acute ischemic syndrome falls between chronic stable angina and acute myocardial infarction (MI) in the clinical spectrum of coronary artery diseatse (CAD), but biologically reflects CAD in its most dangerous form. While the death rate from Mi has fallen in recent years, the rate of hospitalization for unstable angina continues to rise, this likely reflects an increase in the total number of CAD survivors with complex coronary disease, who are living longer due to advances in CAD management. lt is therefore likely that unstable angina will become an even more frequent problem in the future. Newer diagnostic and treatment modalities make it possible to target more precisely the underlying biologic insult in unstable angina patients and therby improve survival, prevent MI, reduce hospital length of stay and prevent disability and subsequent ischemia-related long-term complications.The antithrombotic therapy with heparin plus aspirin reduces the rate of ischemic events in patients with unstable coronary artery disease. Low-molecular-weight heparin are a new class of anticoagulants that are replacing heparin for many indications, has a more predictable anticoagulant effects than standard unfractionated heparin, is easier to administer, and does not require monitoring. This review aims to summarize and to comment on the principal findings of this topic.

Palavras-chave : Acute ischemic syndrome; unfractionated heparin; low-molecular-weight heparin.